---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-098289"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2024-08-19T23:59:59+00:00"
generated_at: "2026-05-31T08:39:50.813414+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kineta reopens VISTA-101 trial; 30 of 39 patients enrolled; KVA12123 safe

## Summary
- Kineta reopened enrollment in VISTA-101 Phase 1/2 trial for KVA12123; expects full enrollment by end of 2024.
- 30 of projected 39 patients enrolled; cleared 5th of 6 monotherapy dose levels and 2 of 4 combination cohorts.
- Initial results showed partial response and stable disease in combo cohorts; durable stable disease in monotherapy.
- KVA12123 demonstrated no dose-limiting toxicities and no CRS-associated cytokines at any dose level.
- TuHURA has exclusive right to negotiate acquisition until Oct 1, 2024 (extendable) after $5M nonrefundable payment.

## SEC filing metadata
- accession: 0000950170-24-098289
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2024-08-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000095017024098289/0000950170-24-098289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000095017024098289/ktra-20240819.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-098289
- JSON: https://secwatch.observer/filing/0000950170-24-098289.json
- Plain text: https://secwatch.observer/filing/0000950170-24-098289.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.